More on ACTU
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.20 |
|
|||
| Open | $3.12 | ||||
| 52 Wk High | $6.07 | ||||
| 52 Wk Low | $3.89 | ||||
| Day High | $3.24 | ||||
| Day Low | $2.86 | ||||
| P/E | 19.07 | ||||
| EPS | $0.15 | ||||
| Volume | 83,287 | ||||
- Actuate Therapeutics to Present at The Citizens Life Sciences Conference
- Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Form 4 ACTUATE THERAPEUTICS, For: Feb 13 Filed by: SCHMITT DANIEL M
- Actuate Therapeutics plans phase 1/2 trial for elraglusib tablet
- Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
- H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)
- Form 8-K ACTUATE THERAPEUTICS, For: Jan 12
- Actuate Therapeutics reports survival benefit in pancreatic cancer trial
- Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metast
- Form 4 ACTUATE THERAPEUTICS, For: Jan 05 Filed by: THOMSON TODD S
Entities mentioned with ACTU
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Roth Capital | View Related Stories »
- S1 | View Related Stories »
- IPO | View Related Stories »
- Trading Radar | View Related Stories »
- Show More...
